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An increasing number of breast cancer (BC) survivors are at risk of developing contralateral 
breast cancer (CBC). We aimed to investigate the influence of various adjuvant systemic 
regimens on, subtype-specific, risk of CBC. 
 
Methods 
This population-based cohort study included female patients diagnosed with first invasive BC 
between 2003-2010; follow-up was complete until 2016. Clinico-pathological data were obtained 
from the Netherlands Cancer Registry, and additional data on receptor status through linkage 
with PALGA: the Dutch Pathology Registry. Cumulative incidences (death and distant 
metastases as competing risk) and hazard ratios (HRs) were estimated for all invasive 
metachronous CBC, and CBC-subtypes. 
 
Results 
Of 83,144 BC patients, 2,816 developed a CBC; the 10-year cumulative incidence was 3.8% 
(95% confidence interval [CI]=3.7-4.0%).  Overall, adjuvant chemotherapy: HR=0.70; 
95%CI=0.62-0.80, endocrine therapy: HR=0.46; 95%CI=0.41-0.52, and trastuzumab with 
chemotherapy: HR=0.57; 95%CI=0.45-0.73 were strongly associated with a reduced CBC risk. 
Specifically, taxane-containing chemotherapy (HR=0.48; 95%CI=0.36-0.62) and aromatase 
inhibitors (HR=0.32; 95%CI=0.23-0.44) were associated with a large CBC risk reduction. More 
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ER-positive CBC (HR=0.41; 95%CI=0.36-0.47), but not ER-negative CBC (HR=1.32, 
95%CI=0.90-1.93), compared to no endocrine therapy. Patients receiving chemotherapy for ER-
negative first BC had a higher risk of ER-negative CBC from 5 years of follow-up (HR=2.84; 
95%CI=1.62-4.99), compared to patients not receiving chemotherapy for ER-negative first BC. 
 
Conclusion  
Endocrine therapy, chemotherapy, as well as trastuzumab with chemotherapy reduces CBC risk. 
However, each adjuvant therapy regimen had a different impact on the CBC-subtype 
distribution. Taxane-containing chemotherapy and aromatase inhibitors were associated with the 














Breast cancer (BC) survival has increased considerably, largely as a result of increasing use of 
(neo)adjuvant therapies[1]. As a consequence, a greater number of women are at risk of 
developing a second primary tumor in the contralateral breast. Studies have shown that the 10-
year risk of contralateral breast cancer (CBC) is 4-7%[2-5].  
There is increasing evidence that patients who received adjuvant endocrine therapy or 
chemotherapy for their first BC have a lower risk of developing CBC. The Early Breast Cancer 
Trialists’ Collaborative Group (EBCTCG) showed that 5-year tamoxifen use was associated with 
a 38% reduction in CBC risk after 10 years of follow-up[6]; and adjuvant chemotherapy with a 
20% decrease[7]. 
CBC patients may have a worse prognosis compared to patients with unilateral BC[2, 4, 
8, 9]. An explanation for this worse prognosis, besides having been diagnosed with yet another 
cancer, may be found in the impact of adjuvant systemic therapy on CBC tumor biology[9], or 
due to misclassification of metastatic disease as a CBC[8]. 
Little is known about the influence of adjuvant systemic therapy on the (hormone) 
receptor subtype of CBC. Some studies showed a higher proportion of estrogen receptor (ER)-
negative CBC among patients who received endocrine therapy for their first BC compared to 
those that did not[10-14]. The studies that evaluated the effects of adjuvant therapy on subtype-
specific CBC risk, however, were based on small numbers. Since adjuvant trastuzumab was 
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We therefore aimed to investigate the influence of different regimens of adjuvant 
endocrine therapy, chemotherapy, and trastuzumab on CBC risk overall and by (hormone) 





The cohort included 83,144 female patients diagnosed with invasive BC, who underwent 
surgery, in 2003-2010 (Figure 1). Patients were selected from the population-based Netherlands 
Cancer Registry (NCR), which contains data on all newly diagnosed cancer patients nationwide. 
Follow-up for all patients started 3 months after first BC diagnosis; therefore, patients who had 
developed distant metastases, CBC, or died within 3 months after diagnosis were excluded.  
 
Patient and tumor characteristics 
The NCR provided clinico-pathological data; follow-up on second cancers and vital status was 
complete until February 1st 2016, but information of recurrences only completely for patients 
diagnosed in 2003-2006 and for 56% in 2007-2008. Pathological information on tumor size (T), 
lymph node status (N), and metastasis (M) collected was coded into tumor stage according to the 
TNM Classification of Malignant Tumors [15]; if pathological information was missing, clinical 
stage was used. 
The NCR records receptor status determined by immunohistochemistry (IHC) since 
2003. Tumors were defined ER-positive or progesterone receptor (PR)-positive when at least 








niversity user on 07 February 2019
7 
 
receptor (HER2) testing and use of adjuvant trastuzumab were implemented from 2005[16]. A 
tumor was considered HER2-positive if IHC 3+ (strong and complete membranous expression in 
>10% of tumor cells) or if IHC 2+ when additional confirmation with in situ hybridization (ISH) 
was available, but considered unknown if ISH confirmation was missing. To overcome 
incompleteness in data on receptor status, all CBC patients were linked to the nationwide 
network and registry of histo- and cytopathology (PALGA)[17] to retrieve where possible 
information on ER/PR/HER2 status for both the first BC and CBC.  
Data were handled in accordance to privacy regulations for medical research[18]. The 




The primary outcome was the development of metachronous CBC, defined as an invasive BC in 
the contralateral breast at least 3 months after the first BC diagnosis. Time at risk ended at the 
date of CBC, distant metastases, death, or end of follow-up, whichever came first. The 
cumulative incidence of CBC was estimated with distant metastases and death as competing 
risks.  
Multivariable Cox Proportional Hazards (CPH) analysis with time since first BC 
diagnosis as time-scale was used to examine the effect of adjuvant systemic therapy 
(chemotherapy, endocrine therapy, trastuzumab, or combined) on CBC risk (hazard ratios 
[HRs]). Subdistribution HRs (SHRs) were calculated accounting for death and distant metastases 
as competing risks. We examined the association between specific types of chemotherapy 
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inhibitors) and CBC risk. All models included all systemic therapies and were adjusted for age 
and stage (III versus I-II) at first BC diagnosis, factors that were previously shown to be 
important predictors of CBC in the Dutch population[2], though in our dataset only stage 
changed the log HR of systemic therapy with >15%. Radiotherapy, ER-status, HER2-status, and 
year of diagnosis did not change the log HR with more than 15%, and were only included for 
sensitivity analyses. Using the nlcheck function in STATA there was no evidence for non-
linearity of age in the multivariable model[19]; therefore age was continuous in all models, 
except for Supplementary Tables 1-3 to illustrate the differences between age categories. Since 
the NCR did not register menopausal status, we used age <50 and ≥50 years as a proxy for pre- 
and post-menopausal status[20]. Potential effect modification of menopause was assessed with a 
specification link test for single-equation models[21, 22]. The proportional hazard assumption 
was assessed using Schoenfeld residuals[23]. We performed sensitivity analyses based on 
selection of years with complete recurrence information, additional censoring on local/regional 
recurrence, and a stricter definition of metachronous CBC (≥1 year after first BC).  
The effect of adjuvant therapy on subtype-specific CBC was estimated using cumulative 
incidence curves, additionally accounting for other CBC-subtypes as competing risks; e.g. to 
determine risk of ER-positive CBC, the following events were treated as competing risks: ER-
negative CBC, ER-unknown CBC, distant metastases, and death. The HER2-specific analysis 
only included patients diagnosed since 2005. Since there was interaction between treatment and 
subtype (Pinteraction<.001), we used joint multivariable CPH analyses[24] to determine the 
association of adjuvant therapies with CBC ER-status in separate models for each of the first BC 
subtypes. We defined subtype as hormone receptor (HR)+/HER2− (i.e. ER+ and/or PR+ & 
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and HR−/HER2− (i.e. ER−/PR−/HER2-). Each model included ER-specific CBC (ER-
positive/ER-negative/ER-unknown), distant metastases, and death as possible outcome. These 
subtype-specific models were adjusted for trastuzumab, age and stage.  
All P-values are two sided; with the statistical significance level set at <.05. Tests for 
heterogeneity between subtypes or follow-up period were performed using the Wald test. 




The cohort included for analyses comprised 83,144 patients diagnosed with invasive first BC 
with a median follow-up of 7.7 years (range 0.3-13.1) (Figure 1). Median time to develop a CBC 
(N=2,816) after a first BC was 4.6 years (range 0.3-12.7). Characteristics of the cohort are 
presented in Table 1. The distributions of adjuvant systemic therapies according to patient and 
tumor characteristics are presented in Supplementary Table 1.  
The 5- and 10-year cumulative incidences of CBC were 1.9% (95% confidence interval 
[CI]=1.8-2.0%) and 3.8% (95%CI=3.7-4.0%), respectively (Supplementary Table 2). CBC 
cumulative incidence increased at a rate of 0.4% per year.  
In a multivariable CPH model (Table 2), treatment with adjuvant chemotherapy 
(HR=0.70; 95%CI=0.62-0.80), endocrine therapy (HR=0.46; 95%CI=0.41-0.52), endocrine and 
chemotherapy (HR=0.35;95%CI=0.31-0.39), and chemotherapy combined with trastuzumab 
(HR=0.57; 95%CI=0.45-0.73) were strongly associated with a reduced CBC risk compared to 
patients who did not receive systemic therapy. Patients receiving trastuzumab combined with 
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95%CI=0.17-0.33; P<.05 compared with any other treatment group; Table 2). Adjustment for 
radiotherapy, year of diagnosis, ER and HER2 status, or taking distant metastases and death as 
competing risks into account, did not substantially alter these results (Supplementary Table 3), 
neither did additional censoring on local and regional recurrence, or a stricter definition of CBC 
(Supplementary Table 4). Radiotherapy was not associated with CBC risk (HR=0.94; 
95%CI=0.86-1.02; Supplementary Table 3). Therapy-specific analysis showed that taxane-
containing chemotherapy was strongly associated with a CBC risk reduction (HR=0.48; 
95%CI=0.36-0.62; Table 2) compared to patients who did not receive chemotherapy; but not 
anthracycline-containing chemotherapy (HR=0.91;95%CI=0.77-1.06). Treatment with aromatase 
inhibitors (HR=0.32; 95%CI=0.23-0.44) was associated with a stronger CBC risk reduction 
compared to tamoxifen (HR=0.48; 95%CI=0.44-0.53) (Pheterogeneity=.01). There was no evidence 
for effect modification between menopausal status and any adjuvant therapy on CBC risk. 
Because the proportional hazard assumption was violated for chemotherapy,  endocrine 
therapy, and trastuzumab, the multivariable CPH analyses were also performed stratified for 
follow-up duration ≤5 and >5 year (Table 2)[25], following higher recurrence risk reductions for 
the period ≤5 years shown by the EBCTCG[6, 26]. In our study, CBC risk was statistically 
significantly stronger reduced in the first 5 years of follow-up among patients who had received 
chemotherapy and endocrine therapy combined (Pheterogeneity<.001), or chemotherapy and 
trastuzumab combined (Pheterogeneity=.04) than in the period >5 years follow-up. However, overall, 
systemic therapy remained statistically significantly associated with a reduced CBC risk >5 years 
of follow-up. 
Patients diagnosed with stage III first BC showed a statistically significantly higher risk 
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metastases and death were taken into account as competing risks (Supplementary Table 1). 
CBC risk did not differ by age at first BC, apart from a lower CBC risk for patients aged 45-54 
(HR=0.88; 95%CI=0.80-0.98) and ≥85 years (HR=0.55; 95%CI=0.37-0.81) compared to patients 
aged 55-64 years.  
A greater proportion of CBCs among patients treated with endocrine therapy was ER-
negative (23.2%), compared to that among patients without endocrine therapy for ER-positive 
first BC (6.9%; Supplementary Table 5). The proportion of ER-negativity between the first BC 
and CBC of all patients did not differ (both 18.3%; Table 1). Among patients with ER-positive 
first BC (Figure 2A), the difference for ER-positive CBC was 3.4% after 10-year of follow-up 
between patients who received endocrine therapy (1.8%; 95%CI=1.6-2.0) and those who did not 
(5.2%; 95%CI=4.9-5.5). Multivariable joint CPH analyses (Table 3) classifying the first BCs in 
four BC subtypes, showed that among patients diagnosed with HR+/HER2− first BC, endocrine 
therapy statistically significantly decreased the risk of ER-positive CBC (HR=0.41; 
95%CI=0.36-0.47), but not ER-negative CBC (HR=1.32; 95%CI=0.90-1.93) (Pheterogeneity=<.001).  
We observed a 10-year cumulative incidence of ER-negative CBC of 1.9% (95%CI=1.6-
2.2) for patients who received chemotherapy for ER-negative first BC, and 1.2% (95%CI=0.9-
1.6) for patients who did not (Figure 2B). Multivariable joint CPH analyses showed that patients 
diagnosed with HR−/HER2− (triple negative) first BC had a higher risk of triple-negative CBC 
when they received adjuvant chemotherapy (HR=1.56; 95%CI=1.00-2.42), compared to patients 
who did not (Supplementary Figure 1). In subsequent analyses within ER-negative tumors 
(insufficient data for triple negatives), we found no association between chemotherapy received 
for ER-negative first BC and risk of an ER-negative CBC in the first 5 years of follow-up 
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treated with chemotherapy after >5 years follow-up (HR=2.84; 95%CI=1.62-4.99), compared to 
patients who did not receive chemotherapy for ER-negative first BC. Therapy-specific analyses 
(Supplementary Table 6) showed a statistically non-significant increased risk of ER-negative 
CBC for anthracycline-containing chemotherapy (HR=1.32; 95%CI=0.86-2.04), which was the 
strongest >5 years of follow-up (HR=1.88; 95%CI=0.91-3.86), but a statistically significant 
decreased risk for taxane-containing chemotherapy (HR=0.36; 0.17-0.75). The combination of 
taxane- and anthracycline-containing chemotherapy was associated with a statistically non-
significant decreased risk of ER-negative CBC (HR=0.59; 95%CI=0.28-1.22; Supplementary 
Table 6). The proportion of HER2-positive CBC was 33.7% for patients treated with 
trastuzumab for HER2-positive first BC (Supplementary Table 7) with a 5-year cumulative 
incidence of 0.4% (95%CI=0.3-0.7; Figure 2C), and this was 12.0% for patients that did not 




In this population-based cohort study comprising 83,144 BC patients, we observed a 10-year 
cumulative incidence of metachronous CBC of 3.8%. Overall, receipt of adjuvant chemotherapy, 
endocrine therapy, and/or trastuzumab with chemotherapy was strongly associated with a 
reduced CBC risk. More detailed analyses showed that endocrine therapy was only associated 
with a reduced risk of ER-positive CBC and did not protect against the development of ER-
negative CBC. Patients receiving chemotherapy for ER-negative first BC had a higher risk of 
ER-negative CBC >5 years of follow-up, compared to patients who did not receive 
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The 10-year cumulative incidence of CBC in our study was relatively low compared to 
earlier studies[3, 4, 27], but consistent with other, more contemporary studies[2, 5, 28, 29]. In 
our study, adjuvant endocrine therapy, chemotherapy, and trastuzumab combined with 
chemotherapy were associated with overall 54%, 30%, and 43% risk reductions of CBC, 
respectively. The risk reductions associated with endocrine therapy and chemotherapy in our 
study are slightly higher than the reductions seen in meta-analyses of the EBCTCG[6, 7, 26]. 
Radiotherapy was not associated with an increased CBC risk, which is consistent with other 
studies with a mean follow-up time <15 years[2, 29-31]. 
We observed a strongly reduced CBC risk among patients treated with taxane-containing 
chemotherapy. The increase in use of taxane-containing chemotherapy coincided with a 
declining trend in CBC incidence over the years (Supplementary Table 2). Unfortunately, we 
have no biological explanation for the different effect of taxanes versus anthracyclines. However, 
our finding is consistent with a randomized adjuvant trial showing an improvement in disease-
free survival for docetaxel and cyclophosphamide (TC) compared with doxorubicin and 
cyclophosphamide (AC)[32]. The WECARE case-control study[33] found a lesser, non-
significant CBC risk reduction among patients treated with taxane-containing or with 
anthracycline-containing chemotherapy of ~0.80, but patients were diagnosed in an earlier period 
(1986-2008) and the study had smaller numbers.  
Little is known about the influence of chemotherapy on subtype distribution of CBC. In 
our study, adjuvant chemotherapy provided for ER-negative first BC was associated with a 
decreased risk of ER-positive CBC, which might partly be explained by chemotherapy-induced 
amenorrhea[34, 35]. However, we found an increased risk of ER-negative CBC for patients 
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possibility is that the ER-negative CBCs that developed >5 years were chemotherapy-induced 
tumors. Although effects were not statistically significant because of small numbers, our therapy-
specific analyses showed that this increased risk was only seen in the anthracycline-containing 
chemotherapy group, which is consistent with earlier reports discussing that anthracyclines might 
increase the risk of development of BC[36, 37]. Possibly the risk is only seen for ER-negative 
CBC because the ER-positive CBCs were prevented due to endocrine therapy irrespectively. The 
protective effect of taxane-containing chemotherapy seemed attenuated when given in 
combination with anthracyclines, which might indicate that the increased effect of anthracyclines 
may be counteracted by taxanes. Thus, anthracycline-containing chemotherapy might induce ER-
negative CBC, but further research will be needed to establish the definite role of anthracyclines 
in second BC development.  
We found a larger reduction in CBC risk among patients who received aromatase 
inhibitors compared to tamoxifen. This finding is consistent with a meta-analysis of randomized 
trials, which observed that the carryover benefit for CBC was larger for patients randomized to 
aromatase inhibitors versus tamoxifen[38]. Although endocrine therapy was associated with an 
overall statistically significantly decreased CBC risk, we and others[33, 39, 40] showed that it 
was particularly effective in reducing risk of ER-positive CBC, while the risk of ER-negative 
CBC did not decrease. This is consistent with endocrine therapy selectively inhibiting growth of 
ER expressing tumor cells, thus reducing the incidence of ER-positive BCs only[6, 41]. 
It was not possible to investigate the individual effect of trastuzumab on CBC risk, since 
all patients received trastuzumab combined with chemotherapy. Besides, we were not able to 
perform multivariable CPH analyses to assess the effect of trastuzumab on HER2-specific CBC 
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suggests a slightly higher risk of HER2-positive CBC for patients treated with, compared to 
patients not treated with trastuzumab. We expected a reduction of HER2-positive CBC after 
trastuzumab as a consequence of elimination of HER2-overexpressing clones[42].   
We observed an increased CBC risk for patients diagnosed with a stage III first BC in the 
cause-specific CPH model, while there was no association when taking death and distant 
metastases into account as competing risks. This suggests that part of CBCs were in fact 
metastases even though these were considered to be by definition a second primary BC. One 
study, assessing the relationship between first BC and CBC using exome sequencing, has shown 
that 12% of CBCs represents metastatic spread from the first BC[43]. We attempted to minimize 
the contribution of metastases to the contralateral breast beforehand by starting follow-up 3 
months after first BC diagnosis, only including patients without distant metastasis at initial 
diagnosis, and censoring for distant metastases during follow-up. Sensitivity analyses showed 
that additional censoring on local and regional recurrence, or a stricter definition of CBC did not 
alter the results (Supplementary Table 4).  
In our study patients aged <35 years did not have a higher CBC risk compared to older 
patients, which is in contrast to findings in a previous cohort study using NCR data, including 
BC patients diagnosed between 1989-2002[2]. A potential explanation for these discrepant 
observations might be the increasing use of adjuvant systemic therapy in the last two decades[2, 
44]. In our study, 96% of all patients aged <35 years at first BC diagnosis received adjuvant 
systemic therapy, while this was 59% in the period 1990-2000[45].  
This study harbors some limitations. Since this study was observational, patients who 
received adjuvant systemic therapy differed with respect to some patient and tumor 
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years of diagnosis included, patients with favorable tumor characteristics could avoid systemic 
therapy following Dutch guidelines[46]. Importantly, in the analyses we adjusted for all these 
characteristics, but the possibility of some unmeasured residual confounding might still exist. 
Follow-up on recurrences was not completely recorded by the NCR. This could influence our 
results, since censoring on distant metastases was not possible for patients outside this period. 
However, sensitivity analyses showed similar results when including only patients diagnosed 
between 2003-2006 in the analyses (Supplementary Table 4). We lacked data on contralateral 
prophylactic mastectomy, which could have resulted in an underestimation of the CBC risk. 
However, our previous cohort study showed that the uptake of contralateral prophylactic 
mastectomy among BC patients (aged <50) is only ~4% in the Netherlands[47]. Therefore, it is 
unlikely that this missing information affected our main conclusions. Finally, we had no data 
available on BRCA1/2 mutation carriership. However, we do not expect that this significantly 
affected our results, since the proportion of carriers is limited in the general population[47]. We 
also lacked data on other germline mutations in genes such as CHEK2 or PALB2, or on breast 
cancer associated single nucleotide polymorphisms. However, since there is no indication that 
these mutation carriers are treated differently with adjuvant systemic therapy compared to non-
carriers[48-50], or that there is interaction with adjuvant systemic therapy[49, 51], we do not 
expect that the absence of these data significantly influenced our results.  
The main strengths of this study were the use of a large population-based cohort 
including all BC patients diagnosed between 2003-2010 in the Netherlands, the comprehensive 
tumor and therapy information, and active follow-up on CBC occurrence, allowing reliable 
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In conclusion, our large population-based study showed a 10-year cumulative CBC 
incidence of 3.8%. Adjuvant systemic therapy strongly reduced CBC risk in a subtype-dependent 
manner. According to this study, there is no clear indication to change current guidelines on 
adjuvant systemic therapy. Further research disentangling true primary CBCs from metastases 















This work was supported by the Alpe d’HuZes/Dutch Cancer Society (KWF Kankerbestrijding) 
(2013-6253 ALPE).  
 
Notes 
The sponsor had no role in the design of the study; the collection, analysis, and interpretation of 
the data; the writing of the manuscript; and the decision to submit the manuscript for publication. 
The authors have no conflicts of interest.  
We thank the registration team of the Netherlands Comprehensive Cancer Organization (IKNL) 
for the collection of data for the Netherlands Cancer Registry (NCR) as well as IKNL staff for 
scientific advice. We acknowledge the PALGA foundation for providing us the linkage with the 
NCR data. We want to thank all patients whose data we used for this study, and clinicians who 















1. Netherlands Cancer Registry (NCR). Survival and prevalence of cancer (2016). Available 
from: http://www.cijfersoverkanker.nl/overleving-prevalentie-51.html. 
2. Schaapveld M, Visser O, Louwman WJ, et al. The impact of adjuvant therapy on 
contralateral breast cancer risk and the prognostic significance of contralateral breast cancer: a 
population based study in the Netherlands. Breast Cancer Res Treat 2008;110(1):189-97. 
3. Gao X, Fisher SG, Emami B. Risk of second primary cancer in the contralateral breast in 
women treated for early-stage breast cancer: a population-based study. Int J Radiat Oncol Biol 
Phys 2003;56(4):1038-45. 
4. Healey EA, Cook EF, Orav EJ, et al. Contralateral breast cancer: clinical characteristics 
and impact on prognosis. J Clin Oncol 1993;11(8):1545-52. 
5. Aalders KC, van Bommel AC, van Dalen T, et al. Contemporary risks of local and 
regional recurrence and contralateral breast cancer in patients treated for primary breast cancer. 
Eur J Cancer 2016;63:118-26. 
6. Davies C, Godwin J, Gray R, et al. Relevance of breast cancer hormone receptors and 
other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised 
trials. Lancet 2011;378(9793):771-84. 
7. Early Breast Cancer Trialists' Collaborative Group. Polychemotherapy for early breast 
cancer: an overview of the randomised trials. Lancet 1998;352(9132):930-42. 
8. Font-Gonzalez A, Liu L, Voogd AC, et al. Inferior survival for young patients with 
contralateral compared to unilateral breast cancer: a nationwide population-based study in the 








niversity user on 07 February 2019
20 
 
9. Hartman M, Czene K, Reilly M, et al. Incidence and prognosis of synchronous and 
metachronous bilateral breast cancer. J Clin Oncol 2007;25(27):4210-6. 
10. Li CI, Daling JR, Porter PL, et al. Adjuvant hormonal therapy for breast cancer and risk 
of hormone receptor-specific subtypes of contralateral breast cancer. Cancer Res 
2009;69(17):6865-70. 
11. Arpino G, Weiss HL, Clark GM, et al. Hormone receptor status of a contralateral breast 
cancer is independent of the receptor status of the first primary in patients not receiving adjuvant 
tamoxifen. J Clin Oncol 2005;23(21):4687-94. 
12. Swain SM, Wilson JW, Mamounas EP, et al. Estrogen receptor status of primary breast 
cancer is predictive of estrogen receptor status of contralateral breast cancer. J Natl Cancer Inst 
2004;96(7):516-23. 
13. Stark A, Lu M, Mackowiak P, et al. Concordance of the Hormone Receptors and 
Correlation of HER‐2/neu Overexpression of the Metachronous Cancers of Contralateral Breasts. 
The breast journal 2005;11(3):183-187. 
14. Kaas R, Peterse JL, Hart AA, et al. The influence of tamoxifen treatment on the 
oestrogen receptor in metachronous contralateral breast cancer. Br J Cancer 2003;88(5):707-10. 
15. Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the 
AJCC cancer staging manual and the future of TNM. Annals of surgical oncology 
2010;17(6):1471-1474. 
16. de Munck L, Schaapveld M, Siesling S, et al. Implementation of trastuzumab in 
conjunction with adjuvant chemotherapy in the treatment of non-metastatic breast cancer in the 








niversity user on 07 February 2019
21 
 
17. Casparie M, Tiebosch A, Burger G, et al. Pathology databanking and biobanking in The 
Netherlands, a central role for PALGA, the nationwide histopathology and cytopathology data 
network and archive. Analytical Cellular Pathology 2007;29(1):19-24. 




19. Jann, B. nlcheck: Stata module to check linearity assumption after model estimation, 
2008. Available from http://ideas.repec.org/. 
20. Hill K. The demography of menopause. Maturitas 1996;23(2):113-27. 
21. Tukey JW. One Degree of Freedom for Non-Additivity. Biometrics 1949;5(3):232-242. 
22. Pregibon D. Goodness of Link Tests for Generalized Linear Models. Journal of the Royal 
Statistical Society. Series C (Applied Statistics) 1980;29(1):15-14. 
23. Schoenfeld DA. Sample-size formula for the proportional-hazards regression model. 
Biometrics 1983;39(2):499-503. 
24. Xue X, Kim MY, Gaudet MM, et al. A comparison of the polytomous logistic regression 
and joint cox proportional hazards models for evaluating multiple disease subtypes in 
prospective cohort studies. Cancer Epidemiol Biomarkers Prev 2013;22(2):275-85. 
25. Kleinbaum DG, Klein M. Survival analysis: Springer; 2010. 
26. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an 
overview of the randomised trials. The Lancet 1998;351(9114):1451-1467. 
27. Broet P, de la Rochefordiere A, Scholl SM, et al. Contralateral breast cancer: annual 








niversity user on 07 February 2019
22 
 
28. Bertelsen L, Bernstein L, Olsen JH, et al. Effect of systemic adjuvant treatment on risk 
for contralateral breast cancer in the Women's Environment, Cancer and Radiation Epidemiology 
Study. J Natl Cancer Inst 2008;100(1):32-40. 
29. Hooning MJ, Aleman BM, Hauptmann M, et al. Roles of radiotherapy and chemotherapy 
in the development of contralateral breast cancer. J Clin Oncol 2008;26(34):5561-8. 
30. Drooger J, Akdeniz D, Pignol JP, et al. Adjuvant radiotherapy for primary breast cancer 
in BRCA1 and BRCA2 mutation carriers and risk of contralateral breast cancer with special 
attention to patients irradiated at younger age. Breast Cancer Res Treat 2015;154(1):171-80. 
31. Pierce LJ, Phillips KA, Griffith KA, et al. Local therapy in BRCA1 and BRCA2 mutation 
carriers with operable breast cancer: comparison of breast conservation and mastectomy. Breast 
Cancer Res Treat 2010;121(2):389-98. 
32. Jones SE, Savin MA, Holmes FA, et al. Phase III trial comparing doxorubicin plus 
cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable 
breast cancer. J Clin Oncol 2006;24(34):5381-7. 
33. Langballe R, Mellemkjaer L, Malone KE, et al. Systemic therapy for breast cancer and 
risk of subsequent contralateral breast cancer in the WECARE Study. Breast Cancer Res 
2016;18(1):65. 
34. Valentini A, Finch A, Lubinski J, et al. Chemotherapy-induced amenorrhea in patients 
with breast cancer with a BRCA1 or BRCA2 mutation. J Clin Oncol 2013;31(31):3914-9. 
35. Zavos A, Valachis A. Risk of chemotherapy-induced amenorrhea in patients with breast 








niversity user on 07 February 2019
23 
 
36. Henderson TO, Moskowitz CS, Chou JF, et al. Breast Cancer Risk in Childhood Cancer 
Survivors Without a History of Chest Radiotherapy: A Report From the Childhood Cancer 
Survivor Study. J Clin Oncol 2016;34(9):910-8. 
37. Leeuwen FEv, Ronckers CM. Anthracyclines and Alkylating Agents: New Risk Factors 
for Breast Cancer in Childhood Cancer Survivors? Journal of Clinical Oncology 2016;34(9):891-
894. 
38. Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis 
of the randomised trials. Lancet 2015;386(10001):1341-1352. 
39. Bouchardy C, Benhamou S, Fioretta G, et al. Risk of second breast cancer according to 
estrogen receptor status and family history. Breast Cancer Res Treat 2011;127(1):233-41. 
40. Gierach GL, Curtis RE, Pfeiffer RM, et al. Association of adjuvant tamoxifen and 
aromatase inhibitor therapy with contralateral breast cancer risk among us women with breast 
cancer in a general community setting. JAMA Oncology 2017;3(2):186-193. 
41. Manna S, Holz MK. Tamoxifen Action in ER-Negative Breast Cancer. Sign Transduct 
Insights 2016;5:1-7. 
42. Guarneri V, Dieci MV, Barbieri E, et al. Loss of HER2 positivity and prognosis after 
neoadjuvant therapy in HER2-positive breast cancer patients. Ann Oncol 2013;24(12):2990-4. 
43. Klevebring D, Lindberg J, Rockberg J, et al. Exome sequencing of contralateral breast 
cancer identifies metastatic disease. Breast Cancer Res Treat 2015;151(2):319-24. 
44. Kollias J, Ellis IO, Elston CW, et al. Prognostic significance of synchronous and 








niversity user on 07 February 2019
24 
 
45. Engelhardt EG, van den Broek AJ, Linn SC, et al. Accuracy of the online prognostication 
tools PREDICT and Adjuvant! for early-stage breast cancer patients younger than 50 years. Eur J 
Cancer 2017;78:37-44. 
46. Oncoline, cancer clinical practice guidelines, versie 1.0. Endocriene therapie. Available 
from: https://www.oncoline.nl/borstkanker. 
47. van den Broek AJ, van 't Veer LJ, Hooning MJ, et al. Impact of Age at Primary Breast 
Cancer on Contralateral Breast Cancer Risk in BRCA1/2 Mutation Carriers. J Clin Oncol 
2016;34(5):409-18. 
48. Schmidt MK, Tollenaar RA, de Kemp SR, et al. Breast cancer survival and tumor 
characteristics in premenopausal women carrying the CHEK2*1100delC germline mutation. J 
Clin Oncol 2007;25(1):64-9. 
49. Kriege M, Hollestelle A, Jager A, et al. Survival and contralateral breast cancer in 
CHEK2 1100delC breast cancer patients: impact of adjuvant chemotherapy. Br J Cancer 
2014;111(5):1004-13. 
50. Cybulski C, Kluzniak W, Huzarski T, et al. Clinical outcomes in women with breast 
cancer and a PALB2 mutation: a prospective cohort analysis. Lancet Oncol 2015;16(6):638-44. 
51. Teraoka SN, Bernstein JL, Reiner AS, et al. Single nucleotide polymorphisms associated 
with risk for contralateral breast cancer in the Women's Environment, Cancer, and Radiation 









niversity user on 07 February 2019
25 
 
Table 1. Patient, tumor, and treatment characteristics of all patients diagnosed with first breast cancer 
between 2003-2010 and subsequent contralateral breast cancer 
Characteristics 
First breast cancer 
No. (%)* 
Contralateral breast cancer 
No. (%)* 
Total 83,144 (100.0) 2,816 (100.0) 
Age at diagnosis, y   
  <35 1,826 (2.2) 22 (0.8) 
  35-44 9,693 (11.7) 153 (5.4) 
  45-54 22,154 (26.7) 523 (18.6) 
  55-64 21,778 (26.2) 801 (28.4) 
  65-74 17,222 (20.7) 771 (27.4) 
  75-84 8,242 (9.9) 444 (15.8) 
  ≥85 2,229 (2.7) 102 (3.6) 
Median age at diagnosis, y (range) 58.5 (19.4-101.3) 63.9 (24.8-97.0) 
Tumor stage   
  I 39,676 (47.7) 1,736 (63.3) 
  II 32,158 (38.7) 703 (25.6) 
  III 11,310 (13.6) 237 (8.6) 
  IV † 68 (2.5) 
  Unknown † 72 
Histological grade   
  Grade 1     17,393 (22.8) 706 (28.9) 
  Grade 2  34,153 (44.8) 1,091 (44.6) 
  Grade 3‡ 24,632 (32.3) 647 (26.5) 
  Unknown 6,966 372 
Morphology   
  Ductal 64,044 (77.0) 2,051 (72.8) 
  Lobular 9,233 (11.1) 380 (13.5) 
  Mixed ductal/lobular 3,013 (3.6) 112 (4.0) 
  Other 6,854 (8.2) 273 (9.7) 
ER status   
  Positive 64,886 (81.7) 2,200 (81.7) 
  Negative  14,579 (18.3) 492 (18.3) 
  Unknown 3,679 124 
PR status   
  Positive 50,674 (66.1) 1,618 (61.6) 
  Negative 26,004 (33.9) 1,010 (38.4) 
  Unknown 6,466 188 
HER2 status§   
  Positive 11,061 (17.3) 335 (12.6) 
  Negative 52,956 (82.7) 2,314 (87.4) 
  Unknown 19,127 167 
Subtype║   
  HR+/HER2− 45,441 (71.8) 1,935 (74.9) 
  HR+/HER2+ 6,957 (11.0) 189 (7.3) 
  HR−/HER2+ 3,618 (5.7) 117 (4.5) 
  HR−/HER2− 7,304 (11.5) 344 (13.3) 
  Unknown 19,824 231 
(Neo)adjuvant therapy for first breast 
cancer 
  
  No (neo)adjuvant therapy¶ 31,290 (37.6) - 
  CT 8,889 (10.7) - 
  ET 17,359 (20.9) - 
  CT + ET 19,923 (24.0) - 
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  CT + ET + TRA 2,955 (3.6) - 
(Neo)adjuvant CT   
  No CT 48,717 (58.6) - 
  Taxane-containing CT# 4,427 (5.3) - 
  Anthracycline-containing CT** 6,802 (8.2) - 
  Taxane- + anthracycline-containing CT 3,590 (4.3) - 
  CT, other or type unknown†† 19.608 (23.6) - 
(Neo)adjuvant ET   
  No ET 42,861 (51.6) - 
  Tamoxifen‡‡ 33,862 (40.7) - 
  Aromatase inhibitors 2,393 (2.9) - 
  Tamoxifen‡‡ + aromatase inhibitors 4,028 (4.8) - 
 
* Percentages may not total 100 because of rounding. ER = estrogen receptor; PR = progesterone receptor; HER2 = 
human epidermal growth factor receptor2; HR+ = hormone receptor positive; HR− = hormone receptor negative; CT 
= chemotherapy; ET = endocrine therapy; TRA = trastuzumab; No. = number 
† Excluded  
‡ Including 12 first breast cancers and 1 contralateral breast cancer that were defined as ‘undifferentiated’ in the  
Netherlands Cancer Registry  
§ HER2 status distribution of first breast cancer from 2005-2010: positive N=10.388 (17.0%), negative N=50.652 
(83.0%), unknown N=2.313 
║ HR+ = ER+ and/or PR+; HR− = ER− and PR− 
¶ No chemotherapy, endocrine therapy or trastuzumab (with or without radiotherapy) 
# The chemotherapeutic combination contains taxanes, but no anthracyclines 
** The chemotherapeutic combination contains anthracyclines, but no taxanes 
†† All other chemotherapeutic drugs and combinations (e.g. CMF) or type unknown 
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Table 2.  Multivariable Cox regression analyses of contralateral breast cancer risk related to the (neo)adjuvant systemic therapy for the first breast 
cancer 
 
* Two-sided Wald test P-value. CT = chemotherapy; ET endocrine therapy = TRA trastuzumab; No. = number; HR = hazard ratio, CI = confidence interval, Ref. 
= reference group 
† Heterogeneity of HRs between ≤5 and >5 years follow-up duration  
‡ Adjusted for age and stage at first breast cancer diagnosis 
§ No chemotherapy, endocrine therapy or trastuzumab (with or without radiotherapy) 
║We compared the CT+ET+TRA group versus the other treatment groups by changing the reference (vs. CT, P<.001) (vs. ET, P<.001) (vs. CT+ET, P=.03) (vs. 
CT+TRA, P<.001) 
¶ Adjusted for trastuzumab therapy, age, and stage at first breast cancer diagnosis 
# The chemotherapeutic combination contains taxanes, but no anthracyclines 
** The chemotherapeutic combination contains anthracyclines, but no taxanes 
†† All other chemotherapeutic drugs and combinations (e.g. CMF) or type unknown 
(Neo)adjuvant systemic therapy 


















HR 95% CI P* 
Model 1: (Neo)adjuvant therapy 
combined‡ 
               
No (neo)adjuvant therapy§ 31,290 1.00 Ref.  4,644 913 1.00 Ref.  26,646 700 1.00 Ref.   
CT 8,889 0.70 0.62-0.80 <.001 2,208 172 0.66 0.56-0.78 <.001 6,681 146 0.79 0.65-0.95 .01 .16 
ET 17,359 0.46 0.41-0.52 <.001 3,678 218 0.42 0.36-0.49 <.001 13,681 149 0.50 0.42-0.60 <.001 .13 
CT + ET 19,923 0.35 0.31-0.39 <.001 2,287 177 0.26 0.22-0.30 <.001 17,636 227 0.50 0.42-0.59 <.001 <.001 
CT + TRA  2,728 0.57 0.45-0.73 <.001 477 43 0.47 0.35-0.64 <.001 2,251 33 0.77 0.54-1.10 .16 .04 
CT + ET + TRA 2,955 0.24║ 0.17-0.33 <.001 261 21 0.20 0.13-0.31 <.001 2,694 17 0.31 0.19-0.51 <.001 .19 
Model 2: Therapy-specific subgroups¶                
(Neo)adjuvant CT                
No CT 48,717 1.00 Ref.  8,341 1,132 1.00 Ref.  40,376 849 1.00 Ref.   
Taxane-containing CT# 4,427 0.48 0.36-0.62 <.001 620 36 0.42 0.30-0.58 <.001 3,807 24 0.64 0.42-0.97 .04 .13 




0.69 0.52-0.91 .009 
475 44 
0.71 0.50-0.99 .05 
3,115 27 
0.66 0.42-1.06 .08 
.83 
CT, other or type unknown†† 19,608 0.70 0.62-0.78 <.001 2,992 232 0.61 0.52-0.71 <.001 16,616 232 0.84 0.71-1.00 .05 .01 
(Neo)adjuvant ET                
No ET 42,861 1.00 Ref.  7,319 1,127 1.00 Ref.  35,542 879 1.00 Ref.   
Tamoxifen‡‡ 33,862 0.48 0.44-0.53 <.001 5,458 352 0.41 0.37-0.47 <.001 28,404 312 0.57 0.49-0.65 <.001 .001 
Aromatase inhibitors 2,393 0.32 0.23-0.44 <.001 407 20 0.31 0.20-0.48 <.001 1,986 18 0.33 0.20-0.53 <.001 .86 
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Table 3. Joint multivariable Cox regression analyses for each of the first tumor subtypes assessing the association of (neo)adjuvant systemic treatment 
of the first breast cancer with subtype-specific contralateral breast cancer risk* 




ER-positive CBC ER-negative CBC 
Pheterogeneity‡ No. of 
CBC 
cases 




HR 95% CI P† 
Model 1: HR+/HER2−§           
Endocrine therapy           
  No endocrine therapy 18,125 860 1.00 Ref.  54 1.00 Ref.   
  Endocrine therapy 27,316 397 0.41 0.36-0.47 <.001 107 1.32 0.90-1.93 .15 <.001 
Chemotherapy           
  No chemotherapy 28,973 1,048 1.00 Ref.  100 1.00 Ref.   
  Chemotherapy 16,468 209 0.56 0.46-0.67 <.001 61 1.15 0.78-1.70 .48 <.001 
Model 2: HR+/HER2+§           
Endocrine therapy           
  No endocrine therapy 2,282 83 1.00 Ref.  8 1.00 Ref.   
  Endocrine therapy 4,675 46 0.43 0.28-0.66 <.001 22 1.22 0.50-2.98 .66 .04 
Chemotherapy           
  No chemotherapy 3,186 96 1.00 Ref.  13 1.00 Ref.   
  Chemotherapy 3,771 33 0.61 0.29-1.27 .19 17 2.33 0.71-6.62 .16 .05 
Model 3: HR−/HER2+§           
Endocrine therapy           
  No endocrine therapy 3,538 77 1.00 Ref.  36 1.00 Ref.   
  Endocrine therapy 80 0 7.15·10-10 1.67·10-10 - 
3.06·10-9 
<.001 2 2.19 0.51-9.36 .29 - 
Chemotherapy           
  No chemotherapy 1,041 19 1.00 Ref.  9 1.00 Ref.   
  Chemotherapy 2,557 58 1.22 0.57-2.64 .61 29 4.01 1.64-9.81 .002 .05 
Model 4: HR−/HER2−§           
Endocrine therapy           
  No endocrine therapy 7,126 124 1.00 Ref.  134 1.00 Ref.   
  Endocrine therapy 178 4 1.22 0.45-3.32 .69 1 0.30 0.04-2.13 .23 .21 
Chemotherapy           
  No chemotherapy  2,255 42 1.00 Ref.  32 1.00 Ref.   
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* Adjusted for trastuzumab therapy, age and stage at first breast cancer diagnosis. CBC = contralateral breast cancer; HR+ = hormone receptor positive; HR− = 
hormone receptor negative; ER = estrogen receptor; HER2 = human epidermal growth factor receptor 2; No = number; HR = hazard ratio; CI = confidence 
interval; Ref. = reference group 
† Two-sided Wald test P-value 
‡ Heterogeneity of HRs between ER-positive and ER-negative CBC 














Figure 1. Overview of the selection of breast cancer patients 
*After notification by the nationwide network and registry of histo- and cytopathology in the 
Netherlands (PALGA) and the national hospital discharge database, trained NCR personnel 
collected data directly from patients’ files. 
 
Figure 2. Cumulative incidence of CBC by ER and HER2 status 
(A) Cumulative incidence curves showing the risk of ER-positive or ER-negative CBC after ER-
positive first breast cancer, stratified for adjuvant endocrine therapy. (B) Cumulative incidence 
curves showing the risk of ER-positive or ER-negative CBC after ER-negative first breast 
cancer, stratified for adjuvant chemotherapy. (C) Cumulative incidence curves showing the risk 
of HER2-positive or HER2-negative CBC after HER2-positive first breast cancer, stratified for 
adjuvant trastuzumab therapy. For these analyses, patients diagnosed with invasive breast cancer 
between 2003-2004 were excluded because trastuzumab was not yet widely prescribed in those 
years. Each panel in the figure consist of two cumulative incidence curves combined (duplicated 
risk table). In all panels, analyses were performed accounting for death, distant metastases, and 
CBC-subtype as competing risks (e.g. for the analysis of ER-positive CBC, the following events 
were treated as competing risks: ER-negative CBC, ER-unknown CBC, distant metastases, and 
death). Abbreviations: BC = breast cancer; CBC = contralateral breast cancer; CT = 
chemotherapy; ET = endocrine therapy; TRA = trastuzumab; ER = estrogen receptor; HER2 = 
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Patients excluded N = 2,804 
 
N = 3 First breast cancer diagnosis 
without cytological or histological 
confirmation 
N = 1,346 Diagnosed with stage IV or 
unknown  
N = 19  Squamous cell carcinoma  
N = 1,436  Patients died, developed 
distant metastases or (synchronous) 
contralateral breast cancer within 3 
months after first breast cancer 
diagnosis  
Patients included in 
analyses 
 
N = 83,144 
Patients diagnosed with 
invasive contralateral 
breast cancer  
 
N = 2,816 
No invasive contralateral 
breast cancer  
N = 80,328 
 
(including contralateral 
breast cancer in situ N = 870) 
The Netherlands Cancer Registry that 
includes all primary tumors diagnosed 
since 1989*  
 
Inclusion criteria: 
• Females aged > 18 years 
• Invasive breast cancer 
• Diagnosed between January 1st 2003 
and December 31st 2010 
• Surgically treated in Dutch hospital 
• No prior invasive cancer (other than 
non-melanoma skin cancer or non-
breast in situ tumors) 
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